---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-109529"
form_type: "8-K"
ticker: "NMTC"
cik: "0001500198"
company_name: "NEUROONE MEDICAL TECHNOLOGIES Corp"
filed_at: "2024-12-17T23:59:59+00:00"
generated_at: "2026-05-29T02:21:07.578908+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# NeuroOne FY2024 product revenue $3.5M (+77%); FY2025 guidance $8-10M (+132-190%)

## Summary
- Product revenue FY2024 $3.5M (+77% YoY); net loss $12.3M vs $11.9M prior year.
- FY2025 product revenue guidance $8-10M (+132-190%); gross margin 47-51% vs 31% in FY2024.
- Received $3M upfront from expanded Zimmer Biomet distribution agreement in Nov 2024; terminated $3M credit facility.
- Net loss Q4 $3.3M vs $3.1M; operating expenses down 12% to $3.0M in Q4.
- Nasdaq compliance: monitoring bid price until Jan 7, 2025; equity restored above $2.5M after Zimmer payment.

## SEC filing metadata
- accession: 0001213900-24-109529
- form_type: 8-K
- ticker: NMTC
- cik: 0001500198
- company_name: NEUROONE MEDICAL TECHNOLOGIES Corp
- filed_at: 2024-12-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1500198/000121390024109529/0001213900-24-109529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1500198/000121390024109529/ea0224944-8k_neuro.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-109529
- JSON: https://secwatch.observer/filing/0001213900-24-109529.json
- Plain text: https://secwatch.observer/filing/0001213900-24-109529.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.